文献速递泌尿生殖与妇科肿瘤放疗

局部晚期宫颈癌同步放化疗患者的结局与预后因素

Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
PubMed 文献 · Radiat Oncol · 2022-08-17

该回顾性研究分析了2014年1月至2017年6月在湘雅医院接受调强放疗联合同步铂类化疗的192例初治局部晚期宫颈癌(IIB-IVA期)患者,中位随访39.5个月,3年总生存率和无进展生存率分别为89.1%和82.8%。多因素分析显示非鳞状细胞癌和腹主动脉旁淋巴结转移是总生存和无进展生存的独立不良预后因素,治疗前血红蛋白较低是PFS的独立不良预后因素。

要点

  • 非鳞状细胞癌和腹主动脉旁淋巴结转移是OS和PFS的独立不良预后因素。
  • 治疗前血红蛋白<126 g/L是PFS的独立不良预后因素。
  • 3年OS率为89.1%,3年PFS率为82.8%,中位随访39.5个月。

核心结论

  • 非鳞状细胞癌和腹主动脉旁淋巴结转移是接受同步放化疗的局部晚期宫颈癌患者OS和PFS的不良预后因素。
  • 治疗前血红蛋白水平较低是PFS的独立预后因素。

研究设计与样本

  • 回顾性分析了2014年1月至2017年6月在湘雅医院接受调强放疗联合同步铂类化疗的192例初治局部晚期宫颈癌(IIB-IVA期)患者。
  • 采用Kaplan-Meier法估计生存率,单因素和多因素Cox比例风险模型评估各因素对OS和PFS的影响,并构建列线图和校准曲线。

主要发现

  • 中位随访时间为39.5个月,3年OS率和PFS率分别为89.1%和82.8%。
  • 非鳞状细胞癌(包括腺癌或腺鳞癌)、晚期(IIIA-IVA期)、初始淋巴结阳性(盆腔或腹主动脉旁淋巴结)以及治疗前血红蛋白水平较低(<126 g/L)的患者生存率较低。
  • 单因素分析中,非鳞状细胞癌、晚期、盆腔或腹主动脉旁淋巴结转移的患者OS较差;非鳞状细胞癌、晚期、盆腔或腹主动脉旁淋巴结转移以及治疗前血红蛋白水平较低的患者PFS较差。
  • 多因素分析中,非鳞状细胞癌和腹主动脉旁淋巴结转移是OS的独立预后参数;非鳞状细胞癌、腹主动脉旁淋巴结转移和治疗前血红蛋白水平较低是PFS的独立预后参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the prognostic factors affecting long-term survival in locally advanced cervical cancer (LACC) patients treated with concurrent chemoradiotherapy (CCRT). METHODS: We retrospectively analyzed 192 naive LACC (stage IIB-IVA) patients who underwent intensity-modulated radiotherapy (IMRT) with concurrent platinum-based chemotherapy in Xiangya Hospital from January 2014 to June 2017. The clinicopathological factors of all patients were collected. To explore the relationship between factors and prognosis, survival rates were estimated by the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards models were used to evaluate the effect of various factors on overall survival (OS) and progression-free survival (PFS). The nomogram and calibration curves were generated on the basis of survival analysis. RESULTS: The median follow-up time was 39.5 months. There-year rates of OS and PFS were 89.1% and 82.8%. LACC patients with non-squamous cell carcinoma [NSCC, including adenocarcinoma or adenosquamous carcinoma (AC/ASC)], advanced stage (IIIA-IVA), initially positive lymph node (pelvic or para-aortic lymph node, PLN/PALN), and a lower pretreatment hemoglobin (HGB) level (< 126 g/L) had lower survival rates. In univariate analysis, patients with NSCC, advanced stage, PLN or PALN metastasis had worse OS. Patients with NSCC, advanced stage, PLN or PALN metastasis, and a lower pretreatment HGB level had worse PFS. In multivariate analysis, NSCC and PALN metastasis were independent prognostic parameters of OS. NSCC, PALN metastasis and a lower pretreatment HGB level were independent prognostic parameters of PFS. CONCLUSIONS: NSCC and PALN metastasis were poor prognostic factors of OS and PFS, a lower pretreatment HGB level was an independent prognostic factor of PFS in LACC patients treated with CCRT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu J, Tang G, Zhou Q, et al. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy. Radiat Oncol. 2022. PMID: 35978412. doi:10.1186/s13014-022-02115-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。